BIOMARIN PHAR. DL-,001 | 69.12 / +0.48% |
Date/Time | 01/19 / 13:30 |
Chg. / Chg.(%) | 0.33 / +0.48% |
Bid | 69.03 / 80 |
Ask | 69.38 / 80 |
Open | 69.23 |
Previous Close | 68.79 |
High | 69.34 |
Low | 69.09 |
Volume [EUR] | 0.00 |
Volume [Units] | 0 |
Price fixings | 11 |
ISIN | US09061G1013 |
Security | BM8 |
Exchange | Düsseldorf |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Vienna Globa.. | 69.33 | ![]() |
154 |
Xetra | 69.32 | ![]() |
50 |
Berlin | 69.62 | ![]() |
30 |
Frankfurt | 69.0400 | ![]() |
0 |
München | 69.04 | ![]() |
0 |
Düsseldorf | 69.12 | ![]() |
0 |
Lang & Schwa.. | 68.88 | ![]() |
|
Stuttgart | 69.280 | ![]() |
|
gettex | 69.040 | ![]() |
|
TradeGate | 69.150 | 425 | |
NASDAQ | 82.9700 | ![]() |
1,306,558 |
Cboe US | 82.85 | 89,343 | |
IEX | 82.89 | ![]() |
62,135 |
Mexico | 1,599.31 | ![]() |
4,200 |
London Inter.. | 81.84 | 295 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire